Takeda Pharmaceutical (TAK) Assets Average (2019 - 2026)

Takeda Pharmaceutical's Assets Average history runs 8 years deep, the most recent figure standing at $99.5 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 3.25% year-over-year to $99.5 billion in Q1 2026; TTM through Mar 2026 was $99.5 billion, a 3.25% increase from a year earlier, with the FY2026 full-year figure at $98.3 billion, down 0.87% from the prior year.
• Assets Average held at $99.5 billion in Q1 2026 per TAK's latest filing, from $99.2 billion in the prior quarter.
• Across five years, Assets Average topped out at $112.6 billion in Q1 2022 and bottomed at $95.1 billion in Q2 2025.
• The 5-year median for Assets Average is $100.6 billion (2023), against an average of $101.9 billion.
• Across the five-year window, Assets Average decreased 10.89% in 2022 and gained 3.25% in 2026, its largest moves.
• Year by year, Assets Average stood at $100.6 billion in 2022, then declined by 1.0% to $99.6 billion in 2023, then slipped by 1.07% to $98.5 billion in 2024, then grew by 0.64% to $99.2 billion in 2025, then grew by 0.35% to $99.5 billion in 2026.
• Per Business Quant, the three latest TAK Assets Average figures stand at $99.5 billion (Q1 2026), $99.2 billion (Q4 2025), and $97.5 billion (Q3 2025).